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Oral Presentations 13was cyclosporine with four doses of methotrexate in 97 patients and
other treatments in 5. Overall survival at 5 years was 61% and re-
lapse-free survival was 56%. The incidence of acute GvHD grades
II-IV was 62% in patients with an LC30 of\0.2  109/L, 33% if
the LC30 was 0.2–1.0  109/L and 25% in patients with an LC30
.1.0  109/L (p 5 0.008). Transplant related mortality (TRM)
was 34% in patients with an LC30\0.2  109 versus 19% (LC30
of 0.2–1.0  109) and 0% (LC30 .1.0  109) (p\0.001). Survival
was significantly higher in 17 patients with an LC30 .1.0  109/L,
compared to 67 patients with an LC30 0.2–1.0  109/L, and 18 pa-
tients with \0.2  109/L (91% vs. 60%, vs. 36% p 5 0.02 and
0.001 respectively). When analyzed as a continuous variable in mul-
tivariate analysis, a higher LC30 was associated with a lower inci-
dence of acute GvHD grades II-IV, improved survival, less relapse
and higher relapse-free survival. Plasma levels of cytokines were mea-
sured in 15 subjects between day 12–32 post-transplant (total 21 sam-
ples). Six patients had a low (\0.2109/L) and 9 patients a high (.1.0
 109/L) LC30. Plasma IL-15 was lower in patients with high LC30
(median 32 pg/ml vs. 56.5 pg/ml, p\0.05 log rank sum). These re-
sults indicate that the LC30 is a robust prognostic factor for trans-
plant outcome in matched unrelated as well as matched related
SCT for myeloid malignancies receiving either BM or PBSC with
or without irradiation conditioning. Further research to identify
the transplant conditions leading to prompt lymphocyte recovery
might lead to global improvements in SCT outcome in unrelated
SCT.28
ADOPTIVE TRANSFER OF NKT CELLS REDUCES GVHD SEVERITY VIA AN
IFN-G AND IL-4 DEPENDENT MECHANISM
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NKT cells, which are CD1d reactive, are thought to play an im-
munoregulatory role in suppressing dysfunctional immune reac-
tions, including graft-versus-host disease (GVHD). However, we
do not know if non-manipulated donor-type NKT can suppress
GVHD or how NKT proliferate and migrate following hemato-
poetic cell transplantation (HCT). We transferred 5.5  105 highly
purified (.95%) NKT (DX51TCR1CD41) from luciferase posi-
tive (luc1) C57BL/6 (H-2b) mice into lethally irradiated Balb/c (H-
2d) recipients with 5 106 T-cell depleted bone marrow (TCD-BM)
from wild-type (WT) C57BL/6 mice, and monitored them by biolu-
minescence imaging (BLI). By day 4 after transfer, a signal was ob-
served in spleen and lymph node (LN) sites, and between days 7
and 10, NKT had also migrated to skin. Total photons emitted
peaked around day 25 after transplantation, followed by a steady de-
cline. To assess the impact of donor-type NKT on GVHD induction
by Tcon, we co-transferred various doses of highly pure WT NKT
at day 0 with 5  106 TCD-BM, followed by 5  105 luc1Tcon at
day 2. We have found that adoptive transfer of as few as 2.5  10 4
NKT can significantly improve survival of mice receiving 5  105
Tcon. Survival with Tcon only was 20% and for Tcon with NKT
was 74%; p 5 0.0023. To determine how NKT reduce GVHD,
we examined intracellular levels of various cytokines in Tcon with
or without 2.5  104 NKT, following HCT. At 8 days after HCT,
mice receiving NKT had fewer TNFa-positive cells from LNs
(CD4: 45% to 27%; CD8 36% to 24%); by day 11, however,
TNFa levels between groups were equivalent. IFN-g levels, which
were high in both NKT treated and untreated groups at day 8
(85%-95%), decreased significantly in NKT treated mice by day
11 (CD4: 40%; CD8: 43%), but were abundant in Tcon only mice
(CD4: 78%; CD8: 80%) (p 5 .0001). NKT from both IL-4 -/-
and IFN-g -/- mice were less effective at suppressing GVHD than
WT NKT, implicating these cytokines in the suppressive mecha-
nism. Finally, we found that NKT do not have a major impact on
the graft-versus-tumor effect of Tcon against a luc1BCL-1 tumor.
These studies indicate that NKT persist in vivo upon adoptive trans-
fer and suppress GVHD, even at extremely low cell numbers, which
is important given the relative paucity of this cell population. The
mechanisms of GVHD suppression appear to be distinct to those
of CD41CD251FoxP31 Treg and involve the production of
IL-4 and IFN-g by NKT and a decrease in Tcon which produce
pro-inflamatory cytokines.29
CEACAM1 REGULATES EXPERIMENTAL GRAFT-VERSUS-HOST-DISEASE
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Carcinoembryonic antigen associated cell adhesion molecule 1
(Ceacam1) is a type I transmembrane glycoprotein that regulates
numerous processes including bacterial colonization of the gastro-
intestinal lumen and leukocyte function. Ceacam1 is expressed on
gut epithelium and activated T cells, particularly in the intestines.
We found that T cells from Ceacam1-/- mice had elevated phos-
phorylation of STAT3. Upon stimulation with anti-CD31CD28,
IL-2, IL-4, IL-6, or IL-12 in vitro, Ceacam1-/- T cells showed hy-
perphosphorylation of corresponding canonical STAT proteins,
indicating that Ceacam1 can regulate the sensitivity of T cells to cy-
tokines and TCR stimulation. Ceacam1-/- T cells also had defec-
tive anergy induction as measured by IL-2 secretion. This was
associated with decreased cleaved caspase 3 (but not decreased ap-
optosis) and hypophosphorylation of STAT1 upon IFNg treat-
ment. We assessed Ceacam1 regulation of T cells in vivo during
GVHD. Ceacam1-/- T cells caused increased mortality and large
intestinal GVHD, had more profound activation (CD25,
CD62L) and expression of integrin a4b7 and demonstrated selec-
tive infiltration of the intestines. By contrast, Ceacam1-overex-
pressing T cells caused significantly less GVHD mortality and
damage to all target organs, which correlated with decreased prolif-
eration and organ infiltration. We also studied Ceacam1 in recipi-
ents of allogeneic bone marrow transplantation (allo-BMT), and
found that compared to wildtype (WT) recipients, Ceacam1-/- re-
cipients with GVHD showed accelerated mortality and increased
damage to the large intestines and thymus. Donor alloactivated
CD4 T cells in Ceacam1-/- allo-BMT recipients had increased ac-
tivation (CD25), and trafficked preferentially to the mesenteric
lymph nodes, small and large bowel, but had decreased accumula-
tion in the liver and peripheral lymph nodes (PLN). Finally, Cea-
cam1-/- mice were more sensitive to radiation injury as
demonstrated by accelerated kinetics of mortality and decreased
numbers of surviving or regenerating small intestinal crypts. We
conclude that Ceacam1 is an important regulator of alloreactivity
during GVHD through its effects on T cell (allo)activation, prolif-
eration, trafficking, cytokine sensitivity, and anergy. Moreover,
Ceacam1 expression on gut epithelium regulates sensitivity to
radiation injury, T cell alloreactivity, and intestinal GVHD.30
ELAFIN IS A BIOMARKER OF GRAFT VERSUS HOST DISEASE OF THE SKIN
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There are no plasma biomarkers specific to any of the three target
organs of acute graft versus host disease (GVHD): skin, GI tract
and liver. We sought to identify a biomarker for skin GVHD in
an initial discovery step using an intact proteomic analysis system.
We compared plasma pooled from ten patients with skin GVHD
only (sGVHD) to ten patients without GVHD (–GVHD) to ten pa-
tients with GI tract GVHD only (giGVHD). Of four candidate
proteins that were both significantly elevated only in the plasma
of sGVHD and that could be measured by ELISA, we selected ela-
fin, an epidermal proteinase inhibitor that is induced by TNF-a and
found in inflamed epidermis. We measured levels of elafin
14 Oral Presentations(expressed hereafter as mean6SEM pg/ml) in individual samples of
the discovery set confirming that they were significantly higher in
sGVHD compared to giGVHD or –GVHD plasma, respectively
(13,31262456 vs 39686537 vs 32576332, p\.0001). In samples
available from 113 sGVHD and 256 –GVHD patients, we deter-
mined whether elafin levels measured 7 days prior to clinical onset
predicted a subsequent occurrence of sGVHD; they were 1.26 fold
higher in patients who developed sGVHD (42796222 vs
34486108, p5 .001). We then analyzed a validation set of 429 pa-
tients: 275 (64%) –GVHD and 154 (36%) sGVHD. There were no
significant differences for patient characteristics and sample collec-
tion between groups. Elafin levels were two fold higher in sGVHD
plasma as compared to –GVHD plasma (75326488 vs 39256112,
p\.0001). We analyzed whether elafin levels provided prognostic
information regarding eventual maximum stage, transplant-related
mortality (TRM) and overall survival (OS). We divided the patients
using a threshold level of elafin that provided 85% specificity (5500
pg/ml). The group with the high levels of elafin (elafinhigh) com-
prised 29% of the population and developed more severe
skin GVHD than the group with low levels, experienced
significant greater TRM and lower OS; these differences remained
significant when adjusted for age, conditioning intensity, donor and
HLA-match.
Table 1. Correlating low/high elafin withmaximum skin stage,
TRM and OS
Maximumskin
stagep-
value*1 year
TRMp-
value*4 years
OSp-
value*0-1 2-4Low elafin
(%, 95% CI)83%
(78-87%)17%
(13-22%)\ 0.001 7%
(4-11%)0.008 35%
(27-36%)0.001High elafin
(%, 95%
CI)39%
(30-48%)61%
(52-70%)18%
(11-25%)53%
(47-60%)*p-value is adjusted for age, conditioning intensity, donor and HLA
match
Within the 154 patients with sGVHD, those elafinhigh had a mor-
tality-hazard ratio of 1.98 (p 5 .003) that remained significant (p 5
.017) after adjusting for stage of sGVHD, demonstrating an inde-
pendent association of mortality risk with elafin levels. We conclude
that elafin is a novel biomarker for sGVHD that can provide impor-
tant predictive, diagnostic and prognostic information, including
long term survival.31
HOST NATURAL KILLER T CELLS INDUCE AN IL-4 DEPENDENT EXPAN-
SION OF DONOR CD41CD251FOXP31 TREGS THAT PROTECTS AGAINST
LETHAL ACUTE GRAFT-VERSUS-HOST DISEASE
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Regulatory CD41CD251Foxp31 T cells (Tregs) and regulatory
natural killer T (NK T) cells have each been shown to regulate
graft-versus-host disease (GVHD), and interactions between NK T
cells and Treg populations via IL-2 pathways has been shown in vitro
or related to myasthenia gravis protection in syngeneic murine model
systems. Though we have previously demonstrated interactions be-
tween these two regulatory cell populations after MHC-mismatched
allogeneic bone marrow transplantation (allo-BMT) (ASBMT 2007),
the mechanisms of this interaction were not previously known. We
now show that host NKT cells can mediate, via cytokine secretion,
the in vivo proliferative expansion of potent donor Treg allosuppres-
sors that prevents lethal GVHD in mice after conditioning with frac-
tionated lymphoid irradiation (TLI) and anti-T cell serum (ATS)
followed by MHC-mismatched allo-BMT. Protection from day 6 do-
nor CD81T cell proliferation by in vivo CFSE dilution, histopatho-
logic evidence of tissue injury in colon, and significant day 6
proliferation of donor Tregs, all features seen in wild-type TLI/ATS conditioned hosts, were lost in TLI/ATS-treated NKT cell-de-
ficient Jalpha18-/- hosts (p\ 0.01) and IL-4-/- hosts (p\ 0.01), or
when CD41CD251T cells were depleted from the donor transplant
(p\0.01). Chimeric donor Tregs expanded in vivo after TLI’/ATS
and allo-BMT were potent suppressors of donor responders in 72-
hour MLR against host or third-party stimulators, comparable to
wild-type sorted Treg. Add-back of wild-type donor CD41CD251
T cells to the CD25-depleted donor transplant or add-back of wild-
type (p 5 0.001) but not IL-4-/- (p 5 0.11) host NKT cells to NK
T-deficient hosts restored both donor Treg proliferation and protec-
tion from day 6 donor CD81T cell proliferation, indicating that host
NKT cell-induced proliferation of donor Tregs and protection from
donor CD8-mediated colitis was IL-4-dependent. In conclusion, our
findings show that transplantation strategies designed to preserve
host regulatory cells can augment in vivo donor Treg expansion
through an IL-4 dependent mechanism after allogeneic hematopoi-
etic cell transplantation (HCT), and demonstrate mechanisms by
which key host and donor regulatory populations can form
an immunoregulatory bridge helping to cross MHC barriers to
regulate GVHD after allogeneic BMT.32
DONOR KIR 3DS1 IS ASSOCIATED WITH LESS ACUTE GVHD FOLLOWING
UNRELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
FOR HEMATOLOGIC MALIGNANCIES
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Background:Although the activating killer Ig-like receptor (KIR)
3DS1 has been implicated in malignancies, infections, and autoim-
mune diseases, the data for a clinical impact of donor KIR 3DS1 in
the hematopoietic cell transplantation (HCT) setting are heteroge-
nous. We determined the influence of donor activating KIR on risks
of GVHD, relapse, and mortality in a large cohort of unrelated
transplants facilitated by the NMDP.
Methods: Donor KIR typing was performed for 1092 patients re-
ceiving transplants between 1995 and 2002 from 9/10 or 10/10 HLA
allele matched unrelated donors following myeloablative condition-
ing for the treatment of hematologic malignancies with data provided
by the CIBMTR. 59% of transplants were 10/10 matched with typing
verified through the NMDP retrospective typing program. Cox re-
gression was used to examine the association between KIR and
HCT outcome. Models were adjusted for age, disease severity, do-
nor/patient gender, T-cell depletion, stem cell source, conditioning,
and degree of HLA mismatch.
Results: 34% (n5 364) of donors were KIR 3DS1 positive. The
presence of donor 3DS1 was associated with a statistically signifi-
cant decrease in grade II-IV acute GvHD [OR 0.71 (0.55–0.92,
p 5 0.009)] and a suggestive association with decreased mortality
[HR 0.86 (0.74–1.01, p 5 0.07)], but relapse was similar [HR
0.97 (0.73–1.29, p 5 0.82)]. Because 3DS1 defines a subset of
KIR B haplotypes, we examined the influence of donor KIR haplo-
types on outcomes. Although there was a trend, donor KIR haplo-
type B (AB, BB, BX; n5 714) was not associated with a statistically
significant decrease in grade II-IV aGvHD compared to donor AA
haplotypes [OR 0.87 (0.74–1.0 3, p 5 .10)]. Grade II-IV aGvHD
was similar for donor B haplotypes lacking 3DS1 (n 5 350) com-
pared to the AA haplotype or B haplotype with 3DS1 [OR 1.05
(0.89–1.2 4, (p 5 0.54)], but B haplotypes lacking 3DS1 had a sug-
gestively higher rate of grade II-IV aGvHD compared to B haplo-
types with 3DS1 [OR 1.20 (0.99–1.4 6, (p5 0.07)]. The presence of
other activating KIR (2DS1, 2DS2, 2DS3) was not statistically
significantly associated with HCT outcome. KIR 2DS5, however,
was associated with a trend toward decreased mortality [HR 0.85
(0.72–1.0 1, p 5 0.07)].
Conclusion: For patients with hematologic malignancies receiv-
ing an unrelated HCT, presence of donor KIR 3DS1 was associated
with less grade II-IV acute GvHD and may be associated with
improved survival.
